scholarly journals Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology

2020 ◽  
Vol 18 (3) ◽  
pp. 329-354 ◽  
Author(s):  
Thomas W. Flaig ◽  
Philippe E. Spiess ◽  
Neeraj Agarwal ◽  
Rick Bangs ◽  
Stephen A. Boorjian ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Clinical Practice ◽  
Urothelial Carcinoma ◽  
Clinical Practice Guidelines ◽  
Practice Guidelines ◽  
Urothelial Bladder Cancer ◽  
Nccn Guidelines ◽  
Urothelial Bladder ◽  
Biomarker Testing ◽  
Muscle Invasive

This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Bladder Cancer focuses on the clinical presentation and workup of suspected bladder cancer, treatment of non–muscle-invasive urothelial bladder cancer, and treatment of metastatic urothelial bladder cancer because important updates have recently been made to these sections. Some important updates include recommendations for optimal treatment of non–muscle-invasive bladder cancer in the event of a bacillus Calmette-Guérin (BCG) shortage and details about biomarker testing for advanced or metastatic disease. The systemic therapy recommendations for second-line or subsequent therapies have also been revised. Treatment and management of muscle-invasive, nonmetastatic disease is covered in the complete version of the NCCN Guidelines for Bladder Cancer available at NCCN.org. Additional topics covered in the complete version include treatment of nonurothelial histologies and recommendations for nonbladder urinary tract cancers such as upper tract urothelial carcinoma, urothelial carcinoma of the prostate, and primary carcinoma of the urethra.

Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology

2021 ◽  
Vol 19 (3) ◽  
pp. 329-359
Author(s):  
Al B. Benson ◽  
Alan P. Venook ◽  
Mahmoud M. Al-Hawary ◽  
Mustafa A. Arain ◽  
Yi-Jen Chen ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Clinical Practice ◽  
Clinical Practice Guidelines ◽  
Practice Guidelines ◽  
Systemic Therapy ◽  
Checkpoint Inhibitors ◽  
Therapy Options ◽  
Nccn Guidelines ◽  
Positive Treatment ◽  
Biomarker Testing

This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Colon Cancer focuses on systemic therapy options for the treatment of metastatic colorectal cancer (mCRC), because important updates have recently been made to this section. These updates include recommendations for first-line use of checkpoint inhibitors for mCRC, that is deficient mismatch repair/microsatellite instability-high, recommendations related to the use of biosimilars, and expanded recommendations for biomarker testing. The systemic therapy recommendations now include targeted therapy options for patients with mCRC that is HER2-amplified, or BRAF V600E mutation–positive. Treatment and management of nonmetastatic or resectable/ablatable metastatic disease are discussed in the complete version of the NCCN Guidelines for Colon Cancer available at NCCN.org. Additional topics covered in the complete version include risk assessment, staging, pathology, posttreatment surveillance, and survivorship.

The Influence of Access Related Factors on Adherence to Clinical Practice Guidelines for Muscle Invasive Bladder Cancer

2014 ◽  
Vol 1 (3) ◽  
pp. 127-133 ◽  
Author(s):  
C.J. Stimson ◽  
Matthew J. Resnick ◽  
Sanjay G. Patel ◽  
Harras B. Zaid ◽  
Michael S. Cookson ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Clinical Practice ◽  
Clinical Practice Guidelines ◽  
Practice Guidelines ◽  
Invasive Bladder Cancer ◽  
Muscle Invasive Bladder Cancer ◽  
Related Factors ◽  
Muscle Invasive

scholarly journals Management of Non-Muscle-invasive Bladder Cancer: Quality of Clinical Practice Guidelines and Variations in Recommendations

2019 ◽  
Author(s):  
Jing Zhang ◽  
Yunyun Wang ◽  
Hong Weng ◽  
Danqi Wang ◽  
Fei Han ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Clinical Practice ◽  
Clinical Practice Guidelines ◽  
Practice Guidelines ◽  
Bladder Tumour ◽  
Invasive Bladder Cancer ◽  
Muscle Invasive Bladder Cancer ◽  
The Past ◽  
Muscle Invasive

Abstract Abstract Background: Bladder cancer (BC) has become a major worldwide public health issue, especially non-muscle-invasive bladder cancer (NMIBC). A flood of related clinical practice guidelines (CPGs) have emerged; however, the quality and recommendations of the guidelines are controversial. We aimed to appraise the quality of the CPGs for NMIBC within the past 5 years and compare the similarities and differences between recommendations for therapies. Methods: A systematic search to identify CPGs for NMIBC was performed using electronic databases (including PubMed, Embase, Web of Science), guideline development organizations, and professional societies from January 12, 2014 to January 12, 2019. The Appraisal of Guidelines Research & Evaluation (AGREE) II instrument was used to evaluate the quality of the guidelines. Intraclass correlation coefficient (ICC) analysis was performed to assess the overall agreement among reviewers. Results: Nine CPGs were included. The overall agreement among reviewers was excellent. The interquartile range (IQR) of scores for each domain were as follows: scope and purpose 69.44% (35.42%, 85.42%); stakeholder involvement 41.67% (30.56%, 75.00%); rigour of development 48.96% (27.08%, 65.63%); clarity and presentation 80.56% (75.00%, 86.11%); applicability 34.38% (22.92%, 40.63%) and editorial independence 70.83% (35.42%, 85.42%). The NICE, AUA, EAU and CRHA/CPAM clinical practice guidelines consistently scored well in most domains. It was generally accepted that the transurethral resection of bladder tumour (TURBT) and intravesical chemotherapy should be performed in the management of bladder cancer. The application of chemotherapy was highly controversial in high risk NMIBC. The courses of BCG maintenance were similar and included 3 years of therapy at full maintenance doses. Conclusions: The quality of NMIBC guidelines within the past 5 years varied, especially regarding stakeholders, rigour and applicability. Despite many similarities, the recommendations had some inconsistencies in the details.

scholarly journals Management of Urothelial Bladder Cancer in Clinical Practice: Real-World Answers to Difficult Questions

2019 ◽  
Vol 15 (8) ◽  
pp. 421-428 ◽  
Author(s):  
Nataliya Mar ◽  
Farshid Dayyani
Keyword(s):  
Bladder Cancer ◽  
Clinical Practice ◽  
Molecular Mechanisms ◽  
Checkpoint Inhibitors ◽  
Response To Treatment ◽  
Urothelial Bladder Cancer ◽  
Platinum Based Chemotherapy ◽  
Urothelial Bladder ◽  
Muscle Invasive ◽  
Gray Areas

Management of urothelial bladder cancer has historically been challenging as a result of a limited grasp of disease biology and few available systemic therapy options, mainly consisting of platinum-based chemotherapy. Improved understanding of molecular mechanisms underlying pathogenesis of muscle-invasive bladder cancer as well as their correlation with tumor behavior and response to treatment has emerged over the past few years. Remarkable therapeutic advances have been made with the introduction of checkpoint inhibitors, which have changed the course of this disease. Multiple agents with novel mechanisms of action are also actively being explored in ongoing clinical trials. These advances are exciting but may prove challenging in terms of how to apply this constantly evolving plethora of data to actual patients. This review addresses the gray areas and challenging questions that frequently arise in clinical practice.

scholarly journals Optimizing the Clinical Utility of Biomarkers in Oncology: The NCCN Biomarkers Compendium

2014 ◽  
Vol 139 (5) ◽  
pp. 608-611 ◽  
Author(s):  
Marian L. Birkeland ◽  
Joan S. McClure
Keyword(s):  
Clinical Practice ◽  
Clinical Practice Guidelines ◽  
Practice Guidelines ◽  
Treatment Guidelines ◽  
Rapid Development ◽  
Biological Information ◽  
Nccn Guidelines ◽  
Biomarker Testing ◽  
Oncology Care ◽  
Cancer Network

Context The rapid development of commercial biomarker tests for oncology indications has led to confusion about which tests are clinically indicated for oncology care. By consolidating biomarker testing information recommended within National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines), the NCCN Biomarkers Compendium aims to ensure that patients have access to appropriate biomarker testing based on the evaluations and recommendations of the expert NCCN panel members. Objectives To present the recently launched NCCN Biomarkers Compendium. Data Sources Biomarker testing information recommended within NCCN Clinical Treatment Guidelines as well as published resources for genetic and biological information. Conclusions The NCCN Biomarkers Compendium is a continuously updated resource for clinicians who need access to relevant and succinct information about biomarker testing in oncology and is linked directly to the recommendations provided within the NCCN Clinical Practice Guidelines.

scholarly journals Management of non-muscle-invasive bladder cancer: quality of clinical practice guidelines and variations in recommendations

BMC Cancer ◽  
2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Jing Zhang ◽  
Yunyun Wang ◽  
Hong Weng ◽  
Danqi Wang ◽  
Fei Han ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Clinical Practice ◽  
Clinical Practice Guidelines ◽  
Practice Guidelines ◽  
Bladder Tumour ◽  
Invasive Bladder Cancer ◽  
Muscle Invasive Bladder Cancer ◽  
The Past ◽  
Muscle Invasive

Abstract Background Bladder cancer (BC) has become a major worldwide public health issue, especially non-muscle-invasive bladder cancer (NMIBC). A flood of related clinical practice guidelines (CPGs) have emerged; however, the quality and recommendations of the guidelines are controversial. We aimed to appraise the quality of the CPGs for NMIBC within the past 5 years and compare the similarities and differences between recommendations for therapies. Methods A systematic search to identify CPGs for NMIBC was performed using electronic databases (including PubMed, Embase, Web of Science), guideline development organizations, and professional societies from January 12, 2014 to January 12, 2019. The Appraisal of Guidelines Research & Evaluation (AGREE) II instrument was used to evaluate the quality of the guidelines. Intraclass correlation coefficient (ICC) analysis was performed to assess the overall agreement among reviewers. Results Nine CPGs were included. The overall agreement among reviewers was excellent. The interquartile range (IQR) of scores for each domain were as follows: scope and purpose 69.44% (35.42, 85.42%); stakeholder involvement 41.67% (30.56, 75.00%); rigour of development 48.96% (27.08, 65.63%); clarity and presentation 80.56% (75.00, 86.11%); applicability 34.38% (22.92, 40.63%) and editorial independence 70.83% (35.42, 85.42%). The NICE, AUA, EAU and CRHA/CPAM clinical practice guidelines consistently scored well in most domains. It was generally accepted that the transurethral resection of bladder tumour (TURBT) and intravesical chemotherapy should be performed in the management of bladder cancer. The application of chemotherapy was highly controversial in high risk NMIBC. The courses of BCG maintenance were similar and included 3 years of therapy at full maintenance doses. Conclusions The quality of NMIBC guidelines within the past 5 years varied, especially regarding stakeholders, rigour and applicability. Despite many similarities, the recommendations had some inconsistencies in the details.

scholarly journals Management of Non-Muscle-invasive Bladder Cancer: Quality of Clinical Practice Guidelines and Variations in Recommendations

2019 ◽  
Author(s):  
Jing Zhang ◽  
Yunyun Wang ◽  
Hong Weng ◽  
Danqi Wang ◽  
Fei Han ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Clinical Practice ◽  
Clinical Practice Guidelines ◽  
Practice Guidelines ◽  
Bladder Tumour ◽  
Invasive Bladder Cancer ◽  
Muscle Invasive Bladder Cancer ◽  
The Past ◽  
Muscle Invasive

Abstract Background: Bladder cancer (BC) has become a major worldwide public health issue, especially non-muscle-invasive bladder cancer (NMIBC). A flood of related clinical practice guidelines (CPGs) have emerged; however, the quality and recommendations of the guidelines are controversial. We aimed to appraise the quality of the CPGs for NMIBC within the past 5 years and compare the similarities and differences between recommendations for therapies. Methods: A systematic search to identify CPGs for NMIBC was performed using electronic databases (including PubMed, Embase, Web of Science), guideline development organizations, and professional societies from January 12, 2014 to January 12, 2019. The Appraisal of Guidelines Research & Evaluation (AGREE) II instrument was used to evaluate the quality of the guidelines. Intraclass correlation coefficient (ICC) analysis was performed to assess the overall agreement among reviewers. Results: Nine CPGs were included. The overall agreement among reviewers was excellent. The interquartile range (IQR) of scores for each domain were as follows: scope and purpose 69.44% (35.42%, 85.42%); stakeholder involvement 41.67% (30.56%, 75.00%); rigour of development 48.96% (27.08%, 65.63%); clarity and presentation 80.56% (75.00%, 86.11%); applicability 34.38% (22.92%, 40.63%) and editorial independence 70.83% (35.42%, 85.42%). The NICE, AUA, EAU and CRHA/CPAM clinical practice guidelines consistently scored well in most domains. It was generally accepted that the transurethral resection of bladder tumour (TURBT) and intravesical chemotherapy should be performed in the management of bladder cancer. The application of chemotherapy was highly controversial in high risk NMIBC. The courses of BCG maintenance were similar and included 3 years of therapy at full maintenance doses. Conclusions: The quality of NMIBC guidelines within the past 5 years varied, especially regarding stakeholders, rigour and applicability. Despite many similarities, the recommendations had some inconsistencies in the details.

scholarly journals Management of Non-Muscle-invasive Bladder Cancer: Quality of Clinical Practice Guidelines and Variations in Recommendations

2019 ◽  
Author(s):  
Jing Zhang ◽  
Yunyun Wang ◽  
Hong Weng ◽  
Danqi Wang ◽  
Fei Han ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Clinical Practice ◽  
Clinical Practice Guidelines ◽  
Practice Guidelines ◽  
Bladder Tumour ◽  
Invasive Bladder Cancer ◽  
Muscle Invasive Bladder Cancer ◽  
The Past ◽  
Muscle Invasive

Abstract Background: Bladder cancer (BC) has become a major worldwide public health issue, especially non-muscle-invasive bladder cancer (NMIBC). A flood of related clinical practice guidelines (CPGs) have emerged; however, the quality and recommendations of the guidelines are controversial. We aimed to appraise the quality of the CPGs for NMIBC within the past 5 years and compare the similarities and differences between recommendations for therapies. Methods: A systematic search to identify CPGs for NMIBC was performed using electronic databases (including PubMed, Embase, Web of Science), guideline development organizations, and professional societies from January 12, 2014 to January 12, 2019. The Appraisal of Guidelines Research & Evaluation (AGREE) II instrument was used to evaluate the quality of the guidelines. Intraclass correlation coefficient (ICC) analysis was performed to assess the overall agreement among reviewers. Results: Nine CPGs were included. The overall agreement among reviewers was excellent. The interquartile range (IQR) of scores for each domain were as follows: scope and purpose 69.44% (35.42%, 85.42%); stakeholder involvement 41.67% (30.56%, 75.00%); rigour of development 48.96% (27.08%, 65.63%); clarity and presentation 80.56% (75.00%, 86.11%); applicability 34.38% (22.92%, 40.63%) and editorial independence 70.83% (35.42%, 85.42%). The NICE, AUA, EAU and CRHA/CPAM clinical practice guidelines consistently scored well in most domains. It was generally accepted that the transurethral resection of bladder tumour (TURBT) and intravesical chemotherapy should be performed in the management of bladder cancer. The application of chemotherapy was highly controversial in high risk NMIBC. The courses of BCG maintenance were similar and included 3 years of therapy at full maintenance doses. Conclusions: The quality of NMIBC guidelines within the past 5 years varied, especially regarding stakeholders, rigour and applicability. Despite many similarities, the recommendations had some inconsistencies in the details.

scholarly journals New Settings for Immune Checkpoint Inhibitors in Urothelial Cancer

2021 ◽  
Vol 19 (5.5) ◽  
pp. 629-632
Author(s):  
Arlene O. Siefker-Radtke
Keyword(s):  
Bladder Cancer ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitors ◽  
Urothelial Cancer ◽  
Checkpoint Inhibitors ◽  
Urothelial Bladder Cancer ◽  
Nccn Guidelines ◽  
Response To Chemotherapy ◽  
Urothelial Bladder ◽  
Muscle Invasive

The advent of immune checkpoint inhibitors (ICIs) has changed the game in cancer immunotherapy, specifically in the treatment of urothelial bladder cancer. Several clinical trials combining chemotherapy with ICIs have resulted in approvals from the FDA and subsequent revisions within the NCCN Guidelines. The current NCCN Guidelines for Bladder Cancer reflect the most up-to-date, evidence-based data relating to the evaluation and management of urothelial bladder cancer. ICIs have been incorporated into the guidelines as maintenance therapy in response to chemotherapy, sequencing after disease progression from frontline chemotherapy, and for the treatment of non–muscle-invasive bladder cancer.

PD-L1 testing in urothelial bladder cancer: essentials of clinical practice

2020 ◽  
Author(s):  
Mathieu Rouanne ◽  
Camélia Radulescu ◽  
Julien Adam ◽  
Yves Allory
Keyword(s):  
Bladder Cancer ◽  
Clinical Practice ◽  
Urothelial Bladder Cancer ◽  
Urothelial Bladder
Sign in / Sign up

Export Citation Format

Share Document